Compare Citius Pharmaceuticals Inc (CTXR) vs Dover Corp (DOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Dover Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Dover Corp trades at $188.83 (market cap $25.45B). The key difference: Dover Corp is far larger — about 1868.6× Citius Pharmaceuticals Inc's market cap, and Dover Corp pays a 1.11% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Dover Corp for 73 Days on average.
| CTXR | DOV | |
|---|---|---|
Market Cap | $13.62M | $25.45B |
Volume | 132,438 | 661,758 |
Sector | Health | Industrials |
52-Week High | $1.82 | $233.31 |
52-Week Low | $0.48 | $161.16 |
Typical Hold Time | 17 Days | 73 Days |
Enterprise Value | $3.79M | $26.95B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Dover Corporation (DOV) trades at $188.83, up 0.29% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $2.74 exceeding expectations, supported by robust profitability margins including 39.58% gross margin and 13.48% net income margin. Recent acquisitions and product launches demonstrate ongoing business expansion.
Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential. Key risks include technical weakness and cyclical industrial exposure, but strong cash flow generation and dividend history provide stability. The combination of earnings momentum and institutional support suggests long-term value despite near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
